<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625442</url>
  </required_header>
  <id_info>
    <org_study_id>3132012</org_study_id>
    <secondary_id>3132012n</secondary_id>
    <nct_id>NCT01625442</nct_id>
  </id_info>
  <brief_title>Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) in Metabolic Syndrome</brief_title>
  <official_title>Effect of Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) on Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Birjand University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Birjand University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The metabolic syndrome is associated with increased risk of cardiovascular disease and
      diabetes mellitus. The age-adjusted prevalence of the metabolic syndrome in the United States
      is 34% for men and 35% for women. Emerging alternative medicine worldwide led investigators
      to evaluate the efficacy of Crocus sativus (Saffron) and Berberis Vulgaris (barberry fruit)
      in treatment of metabolic syndrome. Serum total cholesterol, serum LDL cholesterol, serum HDL
      cholesterol, serum triglyceride, Fasting Blood Sugar and hematocrit measured before and after
      45 days of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a randomized, placebo controlled, single-blind , efficacy trial with three treatment arms
      the investigators randomly assigned 105 patients with metabolic syndrome to receive barberry
      juice, saffron juice or placebo tablet.

      The aim was to evaluate the efficacy of Crocus sativus (Saffron) and Berberis Vulgaris
      (barberry fruit) in treatment of metabolic syndrome. The metabolic syndrome (syndrome X,
      insulin resistance syndrome) consists of a constellation of metabolic abnormalities that
      confer increased risk of cardiovascular disease (CVD) and diabetes mellitus (DM). The major
      features of the metabolic syndrome include central obesity hypertriglyceridemia, low HDL
      cholesterol, hyperglycemia, and hypertension. Based on data from the National Health and
      Nutrition Examination Survey (NHANES) III, the age-adjusted prevalence of the metabolic
      syndrome in the United States is 34% for men and 35% for Women. Review of literature revealed
      anti-inflammatory, radical-scavenging, antioxidant, cytoprotective, beneficial cardiovascular
      and neural system effects for saffron, potential use for treatment of hypertension,
      tachycardia and some neuronal disorders, such as epilepsy and convulsion, antihypertensive
      and vasodilatory activities. Barberry has promising and selective anti-cancer activities,
      beneficial effects in atherosclerosis, arthritis, coronary heart disease and hepatitis,
      hypotensive property and to promote immunity, prevention of insulin resistance and related
      diseases, neuroprotective, hypolipidemic and antioxidant properties for saffron in animal
      models.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum LDL cholesterol</measure>
    <time_frame>after 45 days of treatment</time_frame>
    <description>Serum LDL cholesterol after 45 days of treatment in three study groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol</measure>
    <time_frame>after 45 days of treatment</time_frame>
    <description>Serum total cholesterol after 45 days of treatment in three study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum HDL cholesterol</measure>
    <time_frame>after 45 days of treatment</time_frame>
    <description>serum HDL cholesterol after 45 days of treatment in three study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum triglyceride</measure>
    <time_frame>after 45 days of treatment</time_frame>
    <description>serum triglyceride after 45 days of treatment in three study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Sugar</measure>
    <time_frame>after 45 days of treatment</time_frame>
    <description>Fasting Blood Sugar after 45 days of treatment in three study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>after 45 days of treatment</time_frame>
    <description>Hematocrit measured after 45 days of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">732</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypertriglyceridemia</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Saffron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saffron treatment group received saffron tablets daily for 45 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Barberry</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Barberry group received barberry tablets daily for 45 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group received placebo tablets daily for 45 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saffron tablet</intervention_name>
    <description>Saffron tablets 100 mg</description>
    <arm_group_label>Saffron</arm_group_label>
    <other_name>crocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Barberry tablet</intervention_name>
    <description>Barberry tablets 200 mg</description>
    <arm_group_label>Barberry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets received daily for 45 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  waist circumference of ≥ 94 cm (males) or ≥ 80 cm (females) plus any two of the
             following:

          -  blood pressure ≥ 130/85 or taking antihypertensive medication,

          -  fasting plasma glucose (FPG) &gt; 100 mg/dL,

          -  serum triglycerides (TG) &gt; 150 mg/dL,

          -  high-density lipoprotein (HDL) &lt; 40 mg/dL in men,and &lt; 50 mg/dL in women-

        Exclusion Criteria:

          -  using insulin or glucose sensitizing medication

          -  preexisting cardiovascular disease

          -  psychiatric problems

          -  non-compliance of patients

          -  not presenting at times determined for treatment and evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tayyebeh Kermani, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant proffessor of anatomy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maryam Navabzadeh, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Traditional iranian medicine specialist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gholamreza Sharifzadeh, M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biostatistician</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javad Hadinia, B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Traditional iranian medicine practitioner</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Narges Saffari, B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health technician</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Khodashenas Roudsari, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Assistant proffessor of internal medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birjand University of medical sciences</name>
      <address>
        <city>Birjand</city>
        <state>South khorasan</state>
        <zip>9714815395</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

